Paritaprevir
Description
Type: small molecule
Groups: approved
Indication: For use in combination with ombitasvir, ritonavir and dasabuvir for the treatment of HCV genotype 1, and with ombitasvir and ritonavir for the treatment of HCV genotype 4.
Accession Number: DB09297 ( DB09297)
Description: Paritaprevir is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1. Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.
Structure:
Prescription Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
Holkira Pak | kit; tablet | Array | oral | 06-01-2015 | Canada | |
Technivie | kit | Array | Array | 24-07-2015 | US | |
Technivie | tablet | Array | oral | 24-11-2015 | Canada | |
Viekira Pak | kit | Array | Array | 19-12-2014 | US |
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
Holkira Pak | kit; tablet | Array | oral | 06-01-2015 | Canada | |
Technivie | kit | Array | Array | 24-07-2015 | US | |
Technivie | tablet | Array | oral | 24-11-2015 | Canada | |
Viekira Pak | kit | Array | Array | 19-12-2014 | US |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
Brand Name | Ingredients |
---|---|
Technivie | Ombitasvir + Paritaprevir + Ritonavir |
Viekira Pak | Dasabuvir + Ombitasvir + Paritaprevir + Ritonavir |
Holkira Pak | Ombitasvir + Dasabuvir + Paritaprevir + Ritonavir |
Technivie | Ombitasvir + Paritaprevir + Ritonavir |
Brand Name | Ingredients |
---|---|
Technivie | Ombitasvir + Paritaprevir + Ritonavir |
Viekira Pak | Dasabuvir + Ombitasvir + Paritaprevir + Ritonavir |
Holkira Pak | Ombitasvir + Dasabuvir + Paritaprevir + Ritonavir |
Technivie | Ombitasvir + Paritaprevir + Ritonavir |
Categories
- No Category
Pharmacology
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Not Available
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
- Not Available
Packagers:
- Not Available
Dosage forms
Form | Route | Strength |
---|---|---|
Kit; tablet | oral | |
Kit | ||
Tablet | oral |
Form | Route | Strength |
---|---|---|
Kit; tablet | oral | |
Kit | ||
Tablet | oral |
Prices
Unit description | Cost | Unit |
---|
Unit description | Cost | Unit |
---|
Patents
Country | Patent Number | Approved | Expires (estimated) |
---|
Interactions
Drug | Interaction |
---|
Drug | Interaction |
---|
Food Interactions:
- Not Available
Taxonomy
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Not Available
substituent:
- Not Available
References
General Reference: Not Available
External Links:
Resource | Link |
---|
Resource | Link |
---|
ATC Codes:
- Not Available
AHFS Codes:
- Not Available
MSDS: Download